| ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner HX Hao, Y Xie, Y Zhang, O Charlat, E Oster, M Avello, H Lei, C Mickanin, ... Nature 485 (7397), 195, 2012 | 1048 | 2012 |
| SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma HX Hao, O Khalimonchuk, M Schraders, N Dephoure, JP Bayley, H Kunst, ... Science 325 (5944), 1139-1142, 2009 | 871 | 2009 |
| Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases YNP Chen, MJ LaMarche, HM Chan, P Fekkes, J Garcia-Fortanet, ... Nature 535 (7610), 148, 2016 | 866 | 2016 |
| Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma X Jiang, HX Hao, JD Growney, S Woolfenden, C Bottiglio, N Ng, B Lu, ... Proceedings of the National Academy of Sciences 110 (31), 12649-12654, 2013 | 447 | 2013 |
| R-Spondin potentiates Wnt/β-catenin signaling through orphan receptors LGR4 and LGR5 H Ruffner, J Sprunger, O Charlat, J Leighton-Davies, B Grosshans, ... PloS one 7 (7), e40976, 2012 | 217 | 2012 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512, 2018 | 196 | 2018 |
| Control of Wnt receptor turnover by R-spondin-ZNRF3/RNF43 signaling module and its dysregulation in cancer HX Hao, X Jiang, F Cong Cancers 8 (6), 54, 2016 | 171 | 2016 |
| Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation S Baltschukat, BS Engstler, A Huang, HX Hao, A Tam, HQ Wang, J Liang, ... Clinical Cancer Research 25 (10), 3164-3175, 2019 | 129 | 2019 |
| Dual allosteric inhibition of SHP2 phosphatase M Fodor, E Price, P Wang, H Lu, A Argintaru, Z Chen, M Glick, HX Hao, ... ACS chemical biology 13 (3), 647-656, 2018 | 125 | 2018 |
| Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus H Huynh, HX Hao, SL Chan, D Chen, R Ong, KC Soo, P Pochanard, ... Molecular cancer therapeutics 14 (5), 1224-1235, 2015 | 121 | 2015 |
| PAS kinase is required for normal cellular energy balance HX Hao, CM Cardon, W Swiatek, RC Cooksey, TL Smith, J Wilde, ... Proceedings of the National Academy of Sciences 104 (39), 15466-15471, 2007 | 113 | 2007 |
| 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors P Sarver, M Acker, JT Bagdanoff, Z Chen, YN Chen, H Chan, B Firestone, ... Journal of medicinal chemistry 62 (4), 1793-1802, 2019 | 94 | 2019 |
| SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors H Lu, C Liu, R Velazquez, H Wang, LM Dunkl, M Kazic-Legueux, ... Molecular cancer therapeutics, molcanther. 0852.2018, 2019 | 84 | 2019 |
| Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma H Huynh, LY Lee, KY Goh, R Ong, HX Hao, A Huang, Y Wang, ... Hepatology 69 (3), 943-958, 2019 | 59 | 2019 |
| The role of PAS kinase in regulating energy metabolism HX Hao, J Rutter IUBMB life 60 (4), 204-209, 2008 | 57 | 2008 |
| Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers HX Hao, H Wang, C Liu, S Kovats, R Velazquez, H Lu, B Pant, M Shirley, ... Molecular cancer therapeutics, molcanther. 0170.2019, 2019 | 50 | 2019 |
| Pancreatic and duodenal homeobox 1 (PDX1) phosphorylation at serine-269 is HIPK2-dependent and affects PDX1 subnuclear localization R An, G da Silva Xavier, F Semplici, S Vakhshouri, HX Hao, J Rutter, ... Biochemical and biophysical research communications 399 (2), 155-161, 2010 | 36 | 2010 |
| Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody J Kou, PR Musich, B Staal, L Kang, Y Qin, ZQ Yao, B Zhang, W Wu, A Tam, ... Journal of translational medicine 16 (1), 253, 2018 | 18 | 2018 |
| Antibodies and methods for WNT pathway-related diseases F Cong, H Hao, LB Klickstein, R Kwong, A Taylor, Y Xie US Patent 9,296,826, 2016 | 10 | 2016 |
| ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES F Cong, H Hao, LB Klickstein, R Kwong, A Taylor, Y Xie US Patent App. 15/073,156, 2018 | 5 | 2018 |
